Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data

  • Entera Bio Ltd ENTX has presented the 6-month bone mineral density (BMD) data from its Phase 2 trial of EB613, an oral formulation of human parathyroid hormone (PTH), for osteoporosis. 
  • The Phase 2 Dose-Ranging study showed clinically significant changes in increases in BMD at the spine, femoral neck, and total hip. 
  • Patients receiving 2.5 mg oral PTH had a placebo-adjusted increase of 3.78% in the lumbar spine (LS) BMD.
  • Additionally, there was a highly statistically significant dose-dependent increase in LS BMD across all dose groups.
  • Pooled 2.5 mg EB613 group had a significant placebo-adjusted 2.76% increase in the femoral neck and a 1.84% increase in total hip BMD. 
  • Significant decrease in serum CTX (of 21% from baseline at 6 months while P1NP was unchanged.
  • The safety profile of EB613 was consistent with and similar to the known profile of injectable PTH (Forteo).
  • Price Action: ENTX stock is down 1.97% at $4.49 during the market session on the last check Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsosteoporosisPhase 2 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!